Pitcairn Co. Trims Position in HCA Healthcare, Inc. (NYSE:HCA)

Pitcairn Co. cut its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 25.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,528 shares of the company’s stock after selling 1,190 shares during the period. Pitcairn Co.’s holdings in HCA Healthcare were worth $1,434,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. MFA Wealth Advisors LLC purchased a new stake in HCA Healthcare in the second quarter worth $27,000. Unique Wealth Strategies LLC purchased a new stake in HCA Healthcare in the second quarter worth $28,000. Bangor Savings Bank grew its stake in HCA Healthcare by 112.5% in the second quarter. Bangor Savings Bank now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 45 shares during the period. GPS Wealth Strategies Group LLC grew its stake in HCA Healthcare by 284.0% in the second quarter. GPS Wealth Strategies Group LLC now owns 96 shares of the company’s stock worth $31,000 after purchasing an additional 71 shares during the period. Finally, Capital Performance Advisors LLP purchased a new stake in shares of HCA Healthcare in the third quarter worth $41,000. 62.73% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Michael S. Cuffe sold 8,358 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total value of $3,221,340.36. Following the completion of the sale, the executive vice president now directly owns 29,678 shares of the company’s stock, valued at $11,438,494.76. This trade represents a 21.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Erol R. Akdamar sold 2,900 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the sale, the insider now directly owns 6,843 shares of the company’s stock, valued at $2,415,579. The trade was a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,155 shares of company stock worth $5,608,990. 1.60% of the stock is owned by corporate insiders.

HCA Healthcare Stock Down 2.2 %

NYSE HCA opened at $324.93 on Friday. The stock’s 50-day moving average price is $379.40 and its 200-day moving average price is $358.35. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 48.71. HCA Healthcare, Inc. has a 52 week low of $245.84 and a 52 week high of $417.14. The company has a market capitalization of $82.30 billion, a P/E ratio of 14.59, a price-to-earnings-growth ratio of 1.28 and a beta of 1.68.

HCA Healthcare Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Friday, December 13th will be given a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a dividend yield of 0.81%. The ex-dividend date of this dividend is Friday, December 13th. HCA Healthcare’s dividend payout ratio is currently 11.85%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on HCA shares. Raymond James cut HCA Healthcare from an “outperform” rating to a “market perform” rating in a research note on Friday. Barclays cut their target price on HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. UBS Group increased their target price on HCA Healthcare from $405.00 to $438.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Morgan Stanley started coverage on HCA Healthcare in a report on Tuesday, September 3rd. They set an “equal weight” rating and a $427.00 price target on the stock. Finally, Royal Bank of Canada upped their price target on HCA Healthcare from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Friday, August 23rd. Six investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $385.00.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.